Compare · ANTX vs LLY
ANTX vs LLY
Side-by-side comparison of AN2 Therapeutics Inc. (ANTX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 6587.8x ANTX ($168.6M).
- Over the past year, ANTX is up 330.3% and LLY is up 52.7% - ANTX leads by 277.6 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 4 for ANTX).
- LLY has more recent analyst coverage (25 ratings vs 13 for ANTX).
- Company
- AN2 Therapeutics Inc.
- Eli Lilly and Company
- Price
- $4.69+0.00%
- $1178.57+0.73%
- Market cap
- $168.6M
- $1.11T
- 1M return
- -2.29%
- +5.00%
- 1Y return
- +330.28%
- +52.71%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 4
- 11
- Recent ratings
- 13
- 25
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ANTX
- Director Aziz Kabeer was granted 2,852 shares, increasing direct ownership by 5% to 59,106 units (SEC Form 4)
- Director Marks Gilbert Lynn was granted 2,789 shares, increasing direct ownership by 4% to 81,873 units (SEC Form 4)
- Director Martin Patricia A. was granted 766 shares, increasing direct ownership by 4% to 18,863 units (SEC Form 4)
- Officer Eizen Joshua M sold $24,803 worth of shares (5,945 units at $4.17), decreasing direct ownership by 3% to 206,554 units (SEC Form 4) to satisfy tax liability
- AN2 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
- Principal Accounting Officer Williams Sarah Joanne sold $1,174 worth of shares (265 units at $4.43), decreasing direct ownership by 0.40% to 66,583 units (SEC Form 4) to satisfy withholding obligation
- AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by AN2 Therapeutics Inc.
- AN2 Therapeutics upgraded by Leerink Partners with a new price target
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend